Use of GLP-1 Receptor Agonists in Portal Hypertension

Understanding Portal Hypertension and Treatment Considerations

Patients with portal hypertension are at risk of developing gastroesophageal varices with risk of bleeding, as noted by the American Association for the Study of Liver Diseases 1
Portal hypertension can lead to ascites and hepatic encephalopathy, according to the European Association for the Study of the Liver 2
Portal hypertensive gastropathy is a complication of portal hypertension, as reported by the Asian Pacific Association for the Study of the Liver 3

Portal hypertension involves complex hemodynamic changes, including increased cardiac output and decreased systemic vascular resistance, as described by the European Society of Cardiology 4
Patients with portal hypertension are hemodynamically vulnerable, particularly those with advanced disease, as stated by the European Association for the Study of the Liver 2

There are no specific guidelines that directly address GLP-1 receptor agonists in portal hypertension, according to the European Society of Cardiology, the European Association for the Study of the Liver, and the American Association for the Study of Liver Diseases 1, 5, 6
Patients with portal hypertension often have impaired liver function, which could theoretically affect drug metabolism, as noted by the European Society of Cardiology 4

Regular monitoring of hemodynamic parameters, including blood pressure, is essential for patients with portal hypertension on GLP-1 receptor agonists, as recommended by the European Society of Cardiology 4
Patients should be monitored for signs of worsening portal hypertension, such as ascites, encephalopathy, and variceal bleeding, as advised by the American Association for the Study of Liver Diseases and the Asian Pacific Association for the Study of the Liver 1, 3
Particular caution is needed in patients with refractory ascites or spontaneous bacterial peritonitis, as these indicate advanced disease with greater hemodynamic vulnerability, as stated by the European Association for the Study of the Liver 2

In patients with esophageal varices or history of variceal bleeding, ensure appropriate prophylaxis is maintained with non-selective beta-blockers or endoscopic band ligation as indicated, as recommended by the American Association for the Study of Liver Diseases and the Asian Pacific Association for the Study of the Liver 1, 3
Patients with portal hypertension are often on multiple medications, so drug interactions should be carefully evaluated, as advised by the European Association for the Study of the Liver 2